NTRK2 and neoplasm: Does such platelet serotonin/NAS/TrkB activation not only increase survival and proliferation of cancer stem-like cells, but also increase macrophage TGFβ, thereby driving wider changes compatible with tumor survival, such as the induction of tolerogenic dendritic cells?